A PHASE Ib, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF CIBISATAMAB IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION
Study of Cibisatamab in Combination with Atezolizumab in Patients with Colorectal Cancer
Sponsor: F. Hoffmann-La Roche Ltd
Enrolling: Male and Female Patients
IRB Number: AAAS1555
U.S. Govt. ID: NCT03866239
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to explore the effects, good or bad, of Cibisatamab, atezolizumab, obinutuzumab, and tocilizumab on patients with Colorectal cancer (CRC). In this study, you will first get treated with obinutuzumab (hereafter referred to as pretreatment with obinutuzumab). About 2 weeks later, you will then get treated with Cibisatamab and atezolizumab. If you have a bad reaction to Cibisatamab and atezolizumab, you may also get treated with tocilizumab. About 50 people will take part in this study.
This study is closed
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have histologically confirmed adenocarcinoma originating from the colon or rectum? Yes No
Have you experienced disease progression during or within 3 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE